Since Unger et al. (1959) reported the successful production of glucagon antisera and development of a radioimmunoassay specific for pancreatic glucagon, a number of investigators have been engaged in the radioimmunological measurement of glucagon.
However, the existence of gut glucagon-like immunoreactivity (gut-GLI) (Sutherland and deDuve, 1964; Makman and Sutherland, 1964) has often rendered difficulty in the specific measurement of pancreatic glucagon, as most of the antisera elicited against pancreatic glucagon exhibited crossreactivity with gut-GLI as well. The antisera obtained by Unger et al. (1968) , 30K and G58, and those produced by Heding (1969) , K40, K47and K964, were proved to be highly specific for pancreatic glucagon and have been widely used for its immunological measurement. However, elicitation of the pancreatic glucagon-specific antisera seemed to be by chance. Assan and Slusher (1972) found that the structure requirements for binding with the pancreatic glucagon-specific antiserum K47were satisfied with a C-terminal region of the glucagon and not with the N-terminal and/or central portions which were shown IMAGAWA et al.
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Japon. February1979 to be responsible for binding with nonspecific antiserum PVP-8. A similar observation was reported by Vinik and Hardcastle (1974) .
This paper described the preparation of pancreatic glucagon-specific antisera using a C-terminal fragment of glucagon obtained by tryptic digestion of bovine/porcine glucagon and characterization of the antisera. Tryptic peptides of pancreatic glucagon Table1shows amino acid ratios in an acid hydrolysate of the pH4-insoluble fraction from the tryptic digest of glucagon. The dansyl end group analysis of the fraction indicated the presence of two major peptides that were terminated with Ala and Arg residues at the N-termini, respectively. Bromer et al. (1957) from the tryptic digest of glucagon were further purified by ion exchange chromatography on Dowex50column of the pH 4-soluble fraction is shown in Fig. la . The chromatographic fractionation of the pH 4-insoluble fraction on DEAE-Sephadex column is shown in Fig. lb . The two major peaks, I and II, in Fig. la and two major peaks, III and IV, in Fig. lb were examined by dansyl end group analysis and amino acid analysis of their acid hydrolysates (Table2).
The analytical data proved that the peaks I, II, III and IV are glucagon 1-12, 13-17, 18-29and19-29fragments, respectively, and that these purified tryptic peptides are able to be used safely as substrates for characterization of the glucagon antisera.
Production of antisera
Production of antisera was attempted in rabbits using as immunogens, the pH 4-insoluble fraction-BSA conjugate, glucagon polymer and syrupy glucagon fibrils. After six injections, production of antiglucagon sera was detected in five rabbits given the conjugate (GC-1, 2, 3, 5 and 6), one given the polymer (PGA-2) and one given the fibrils (GA-10).
Table3 indicates the affinity constants (equilibrium constants) and number of the binding sites to pancreatic glucagon of these seven antisera.
All of the antisera exhibited affinities to the glucagon sufficiently high enough to develop sensitive radioimmunoassay for glucagon.
Characterization
of antisera Crossreactivities of antisera with dog gut-extract:
Using pancreatic mono-component glucagon as standard and125I-glucagon (monoradioiodo form) as tracer, seven antisera obtained and crossreactivities of the antisera with dog gut-extract (gut-GLI) were examined in the systems. show the results of the assays. Crossreactivity with the dog gut-extract was also tested, for comparison, in the system using pancreatic glucagon-specific antiserum30K (Fig.2h) . Antiserum GA10exhibited the highest crossreactivity with the extract and its dilution curve was completely superimposable on the doseresponse curve of the standard pancreatic with GA-10, the other six antisera as well as30K were less reactive with the gutextract.
Relative crossreactivities of the antisera to the extract are listed in Table  4 . The crossreactivity of the present extract in the30K system was comparable to that of the dog gut-extract measured by Eisentraut et al. (1968) in their30K assay system. The antisera of GC-series showed relative crossreactivities ranging from0.64to1.5% of that of GA-10, which seemed to be satisfactorily low in order to discriminate gut-GLI from pancreatic glucagon. From these results, it may be concluded that protein conjugate of the C-terminal fragment of glucagon is an efficient immunogen for production of antisera specific to pancreatic glucagon.
Crossreactivities of antisera with gluantisera of GC-series, GC-5showed a linear indicating an important role of the Arg PG(13-17).
These results with30K are in residue in position 18 in interaction of the well agreement with the data reported by antigen with antiserum30K.
This anti- Faloona and Unger (1974) . Antiserum serum reacted negligibly with PG(1-12) and GC-5 crossreacted with PG(18-29) and Relative crossreactivity of a peptide was calculated by dividing the dose of the standard glucagon required for50% inhibition by that of the corresponding peptide. to the same extent as with pancreatic glucagon. Very little but apparent crossreactivities of GC-5with PG (1-12) and PG (13-17) may be due to trace the contamination of glucagon or/and the Nterminal fragment(s) in the pH4-insoluble fraction that had been used as haptenic antigen. It has become, thus, clear that the C-terminal region-specific antiserum in this study can almost specifically react with pancreatic glucagon and the present results have provided an additional support to the proposal that antibodies specific for pancreatic glucagon interact with the hydrophobic C-terminal region in the molecule (Assan and Slusher, 1972) .
Utilizing the pancreatic glucagon-specific antiserum GC-5, the study on practical radio-immunological measurement of glucagon in biological fluids is now under way.
